Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06656962
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-10-18
Brief Title:
The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis AAGN
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Renmin Hospital of Wuhan University
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TEST-T-AAGN
Brief Summary:
This study is a prospective single-arm open-label exploratory clinical study conducted in subjects with ANCA-associated nephritis AAGN aiming to evaluate the efficacy and safety of Telitacicept in the treatment of AAGN
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None